Tim Watkins - Apr 28, 2025 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Role: CMO & Head of Development
Signature: /s/ Peter Slover, Attorney-in-Fact
Stock symbol: CTNM
Transactions as of: Apr 28, 2025
Transactions value $: $0
Form type: 4
Date filed: 4/28/2025, 04:21 PM
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTNM	Stock Option (right to buy)	Award	$0	+260K		$0.00	260K	Apr 28, 2025	Class A Common Stock	260K	$4.50	Direct	F1
transaction	CTNM	Stock Option (right to buy)	Award	$0	+26K		$0.00	26K	Apr 28, 2025	Class A Common Stock	26K	$4.50	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Options granted outside of the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). One-half of the option shares vest on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.
F2	Options granted outside of the Plan, pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). This grant is subject to a performance-based vesting condition to be satisfied upon the achievement of a particular clinical milestone, based on such performance condition being satisfied within two years of the grant date and subject to the Reporting Person's continuous service.

Content

Options granted outside of the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). One-half of the option shares vest on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.

Options granted outside of the Plan, pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). This grant is subject to a performance-based vesting condition to be satisfied upon the achievement of a particular clinical milestone, based on such performance condition being satisfied within two years of the grant date and subject to the Reporting Person's continuous service.